These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications. Varkas G; Van Praet L; Cypers H; Elewaut D Z Rheumatol; 2013 Aug; 72(6):524-9. PubMed ID: 23756592 [TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743 [TBL] [Abstract][Full Text] [Related]
4. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy? Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554 [TBL] [Abstract][Full Text] [Related]
10. New evidence on the management of spondyloarthritis. Sieper J; Poddubnyy D Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489 [TBL] [Abstract][Full Text] [Related]
12. [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis]. Juanola Roura X; Zarco Montejo P; Sanz Sanz J; Muñoz Fernández S; Mulero Mendoza J; Linares Ferrando LF; Gratacós Masmitja J; García de Vicuña R; Fernandez Carballido C; Collantes Estevez E; Batlle Gualda E; Ariza Ariza R; Loza Santamaría E Reumatol Clin; 2011; 7(2):113-23. PubMed ID: 21794794 [TBL] [Abstract][Full Text] [Related]
13. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Olivieri I; Cantini F; Castiglione F; Felice C; Gionchetti P; Orlando A; Salvarani C; Scarpa R; Vecchi M; Armuzzi A Autoimmun Rev; 2014 Aug; 13(8):822-30. PubMed ID: 24726868 [TBL] [Abstract][Full Text] [Related]
14. Current therapeutics for spondyloarthritis. Toussirot É Expert Opin Pharmacother; 2011 Nov; 12(16):2469-77. PubMed ID: 21988214 [TBL] [Abstract][Full Text] [Related]
15. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251 [TBL] [Abstract][Full Text] [Related]
16. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Toussirot E Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816 [TBL] [Abstract][Full Text] [Related]
17. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? Alsoud D; Vermeire S; Verstockt B Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940 [TBL] [Abstract][Full Text] [Related]
18. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454 [TBL] [Abstract][Full Text] [Related]
19. Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease. Paccou J; Nachury M; Duchemin C; Desreumaux P; Flipo RM; Pariente B Joint Bone Spine; 2019 Oct; 86(5):654-656. PubMed ID: 30711690 [No Abstract] [Full Text] [Related]